We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Department of Justice (DOJ) has appealed Purdue Pharma’s $10 billion bankruptcy settlement that resolved thousands of lawsuits and granted the company’s owners, the Sackler family, immunity from future opioid-related legal proceedings. Read More
Under the Biden administration, the FDA has been able to become “boring” again, while the administration looks toward rebuilding the agency’s reputation and its authority after it took a beating under President Trump. Read More
Bamlanivimab and etesevimab are FDA authorized for treating mild-to-moderate COVID-19 in people 12 years and older who are at high risk of progressing to severe disease. Read More
REGEN-COV is currently authorized to prevent COVID-19 infection in people 12 years and older who have been exposed to the coronavirus and are at high risk of progressing to severe disease. Read More
The House Ways and Means Committee voted 24-19 yesterday to advance the Build Back Better Act with drug pricing reform provisions, shortly after the same reforms failed to make it into the House Energy & Commerce Committee’s version. Read More
The FDA’s vision of an enhanced drug distribution security program that would allow electronic tracing of every shipment is an impossibly complicated project that would take years to build, expose confidential company information and might even run afoul of federal law, said the Healthcare Distribution Alliance (HDA), the national organization that represents pharmaceutical distributors. Read More
The FDA has indicated that it will be asking Pfizer-BioNTech to perform more studies on the COVID-19 vaccine Comirnaty’s booster shot before approving the companies’ supplemental biologics license application (BLA). Read More
Following encouraging talks with the FDA in July, Amylyx Pharmaceuticals plans to submit a new drug application (NDA) for AMX0035, a compound designed to slow neurodegeneration in amylotropic lateral sclerosis (ALS) patients. Read More
The FDA and the European Medicines Agency (EMA) have launched a pilot program to provide parallel scientific advice to applicants seeking marketing authorization from the EMA for hybrid products and for those filing abbreviated new drug applications (ANDAs) with the FDA for complex generic drugs. Read More